Stock listing

AQUIS:EDX EDX Medical Group PLC Share Price

Home listing (AQUIS) of EDX Medical Group PLC

Follow EDX Medical Group PLC into a list and get an email when it puts out news.

EDX Medical Group PLC logo
Ticker
AQUIS:EDX
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
AQUIS
Currency
GBX

What changed lately

Latest news

All EDX Medical Group PLC news

Financings

  • Private placement of new ordinary shares of 1p each

    Aug 24, 2026 · US$3.68M

    Closed: £2.7M raised · £0.14 a share · Warrants at £0.03

    Use of proceeds: To support the expansion of the Company's new employee health screening service.

    Closed Aug 24, 2026

  • Private placement of new ordinary shares

    Feb 16, 2026 · US$4.77M

    Announced: £3.5M · £0.14 a share

    Use of proceeds: Accelerating the prostate cancer programme, developing and delivering diagnostic products and services

    Announced Feb 16, 2026

  • Private placement of new ordinary shares

    Oct 20, 2025 · US$2.68M

    Announced: £2M · £0.14 a share · Oberon Capital

    Dealers: Oberon Capital (lead)

    Buyers: Henrik Kraft

    Use of proceeds: Accelerate commercial activity and develop new products and services, including marketing a testicular cancer testing service

    Announced Oct 20, 2025

  • Convertible loan note

    Oct 20, 2025 · US$2.68M

    Announced: up to £2M

    Buyers: Professor Sir Chris Evans (unsecured CLN agreement for up to £2 million)

    Insiders: CLN of up to £2 million issued to founder and Chief Scientific Officer Professor Sir Chris Evans, a related party transaction

    Use of proceeds: Working capital or growth

    Announced Oct 20, 2025

  • Private placement of new ordinary shares

    Apr 3, 2025 · US$3.89M

    Update: £3M · £0.14 a share · Oberon Capital

    Dealers: Oberon Capital (lead)

    Buyers: Professor Sir Chris Evans (5,285,714 Subscription Shares for £740,000; now owns 36.60% of the issued share capital); Dr Mike Hudson (60,714 Subscription Shares); Martin Walton (60,714 Subscription Shares)

    Insiders: Founder Sir Chris Evans subscribed for 5,285,714 shares for £740,000; CEO Dr Mike Hudson and Deputy Chair Martin Walton each subscribed for 60,714 shares

    Use of proceeds: Accelerate regulatory preparation and scale up production of a new prostate cancer super test

    Announced Mar 20, 2025 · Update Mar 31, 2025 · Update Apr 3, 2025

Read by 6ix AI from the company's releases

EDX Medical Group PLC on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
29 in the last 12 months · 85 in all · newest Nov 17, 2026 · oldest 2022

Where EDX Medical Group PLC is listed

ListingExchangeCountryCurrency
AQUIS:EDX · Home listing · This pageAQUISUnited KingdomGBX
Aquis:EDXQAquisUnited KingdomGBX

Log in to ask 6ix AI your own questions about EDX Medical Group PLC.